Search

Your search keyword '"J.P. Sfakianos"' showing total 12 results
Start Over Author "J.P. Sfakianos"
12 results on '"J.P. Sfakianos"'

1. The inverse correlation between obesity and mortality in patients with metastatic castration resistant prostate cancer: Results from the control arms of ASCENT2, MAINSAL and VENICE trials

Author

D. Cignoli, A. Martini, J.P. Sfakianos, G. Gandaglia, N. Fossati, A. Salonia, F. Barletta, S. Scuderi, D. Robesti, C.A. Bravi, E. Mazzone, G. Rosiello, G. Fallara, L. Nocera, G.O. Cirulli, A. Stabile, A. Briganti, F. Montorsi, W.K. Oh, E.D. Gallagher, and M.D. Galsky

Subjects
Diseases of the genitourinary system. Urology, RC870-923, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Published
2020
Full Text
View/download PDF

2. Predicting toxicity-related Docetaxel discontinuation and survival in metastatic castration-resistant prostate cancer using open phase 3 trial data

Author

A. Martini, A.B. Parikh, G. Gandaglia, N. Fossati, G. Fallara, F. Barletta, S. Scuderi, D. Robesti, D. Cannoletta, R. Leni, V. Cucchiara, C.A. Bravi, E. Mazzone, G. Rosiello, G. Basile, L. Nocera, A. Necchi, M. Moschini, J.P. Sfakianos, M.D. Galsky, W.K. Oh, C. Tsao, F. Montorsi, and A. Briganti

Subjects
Diseases of the genitourinary system. Urology, RC870-923, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Published
2020
Full Text
View/download PDF

3. Neoadjuvant versus adjuvant chemotherapy for upper tract urothelial carcinoma: results from the national cancer database

Author

G. Sorce, A. Martini, J. Pfail, U.G. Falgario, N. Waingankar, G. Gandaglia, N. Fossati, G. Fallara, F. Barletta, S. Scuderi, D. Robesti, D. Cannoletta, D. Cignoli, G. Basile, L. Nocera, G. Rosiello, E. Mazzone, C.A. Bravi, A. Necchi, F. Montorsi, A. Briganti, M.D. Galsky, and J.P. Sfakianos

Subjects
Diseases of the genitourinary system. Urology, RC870-923, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Published
2020
Full Text
View/download PDF

4. Neoadjuvant versus adjuvant chemotherapy for upper tract urothelial carcinoma: Results from the national cancer database

Author

A. Martini, J. Pfail, U.G. Falagario, N. Waingankar, G. Gandaglia, N. Fossati, G. Fallara, F. Barletta, S. Scuderi, D. Robesti, D. Cannoletta, A. Necchi, F. Montorsi, A. Briganti, J. Daza, P.J. Treacy, M.D. Galsky, and J.P. Sfakianos

Subjects
Diseases of the genitourinary system. Urology, RC870-923, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Published
2020
Full Text
View/download PDF

5. Comparing oncological and perioperative outcomes of open versus laparoscopic versus robotic radical nephroureterectomy for the treatment of upper tract urothelial carcinoma: A multicenter, multinational, propensity score-matched analysis

Author

N.C. Grossmann, F. Soria, T. Juvet, A. Potretzka, H. Djaladat, E. Kikuchi, A. Mari, Z. Khene, K. Fujita, J.D. Raman, A. Breda, J.P. Sfakianos, J.L. Pfail, E. Laukhtina, P. Rajwa, M. Pallauf, G.E. Cacciamani, C. Poyet, T. Van Doeveren, J.L. Boormans, A. Antonelli, M. Jamil, G. Ploussard, S.F. Shariat, and B. Pradere

Subjects
Urology
Published
2023

6. Biology of BCG response in non-muscle invasive bladder cancer - 2021 IBCN Updates Part III

Author

M.J. Reike, M.A. Ingersoll, D.C. Müller, T.C.M. Zuiverloon, T. Strandgaard, A.M. Kamat, S.B. Williams, R. Seiler, T. Todenhöfer, L. Dyrskjøt, R. Nawroth, P. Goebell, B. Schmitz-Dräger, J.P. Sfakianos, J. Meeks, A. Horowitz, P.C. Black, University of British Columbia [Vancouver], Inflammation et immunité des muqueuses - Mucosal Inflammation and Immunity, Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Institut Cochin (IC UM3 (UMR 8104 / U1016)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), University of Basel (Unibas), Erasmus University Medical Center [Rotterdam] (Erasmus MC), Aarhus University Hospital, Aarhus University [Aarhus], The University of Texas Medical School at Houston, The University of Texas Medical Branch (UTMB), Technische Universität München = Technical University of Munich (TUM), University Hospital Erlangen = Uniklinikum Erlangen, Icahn School of Medicine at Mount Sinai [New York] (MSSM), and Northwestern University Feinberg School of Medicine

Subjects
MESH: Humans, Bacillus Calmette-Guerin (BCG), MESH: Immunotherapy, Urology, [SDV]Life Sciences [q-bio], Bladder cancer, MESH: Non-Muscle Invasive Bladder Neoplasms, MESH: Adjuvants, Immunologic, MESH: Neoplasm Invasiveness, MESH: Urinary Bladder Neoplasms, MESH: BCG Vaccine, SDG 3 - Good Health and Well-being, Oncology, MESH: Biology, Immunotherapy, MESH: Neoplasm Recurrence, Local, MESH: Administration, Intravesical
Abstract

International audience; Bacillus Calmette-Guerin (BCG) remains the only FDA-approved first-line therapy in patients with high-risk non-muscle invasive bladder cancer. Recurrences, even after adequate BCG therapy, are common and the efficacy of second-line therapies remains modest. Therefore, early identification of patients likely to recur and treatment after recurrence remain critical unmet needs in the clinical care of bladder cancer patients. To address these deficits, a better understanding of the mechanisms of resistance to BCG-therapy is needed. The virtual update of the International Bladder Cancer Network (IBCN) on the biology of response to BCG focused on potential mechanisms and markers of resistance to intravesical BCG therapy. The insights from this meeting will be highlighted and put into context of previously reported mechanisms of resistance to BCG in this review.

Published
2022

7. Elevated HLA-E and NKG2A as a Consequence of Chronic Immune Activation Defines Resistance to M. bovis BCG Immunotherapy in Non-Muscle-Invasive Bladder Cancer

Author

D. Ranti, Y.A. Wang, J. Daza, C. Bieber, B. Salomé, E. Merritt, J.A. Cavallo, E. Hegewisch-Solloa, E.M. Mace, A.M. Farkas, S. Shroff, F. Patel, M. Tran, T. Strandgaard, S. V. Lindskrog, L. Dyrskjøt, J. Qi, M. Patel, D. Geanon, G. Kelly, R.M. de Real, B. Lee, S. Kim-Schulze, T.H. Thin, M. Garcia-Barros, K.G. Beaumont, H. Ravichandran, Y. Hu, Y-C. Wang, L. Wang, D. LaRoche, Y. lee, R.P. Sebra, R. Brody, O. Elemento, A. Tocheva, B. D. Hopkins, P. Wiklund, J. Zhu, M.D. Galsky, N. Bhardwaj, J.P. Sfakianos, and A. Horowitz

Abstract

Mycobacterium bovis Bacillus Calmette-Guerin (BCG), the first-line treatment for non-muscle invasive bladder cancer (NMIBC), promotes the production of inflammatory cytokines, particularly interferon (IFN)-γ. Prolonged inflammation and IFN-γ exposure are known to cause an adaptive immune response, enabling immune escape and proliferation by tumor cells. We investigated HLA-E and NKG2A, a novel T and NK cell checkpoint pathway, as a driver of adaptive resistance in BCG unresponsive NMIBC. We observed ubiquitous inflammation in all patients after BCG immunotherapy, regardless of recurrence status. IFN-γ was shown to drive tumor expression of HLA-E and PD-L1. Further, NKG2A-expressing NK and CD8 T cells were enriched in BCG unresponsive tumors and with enhanced capacity for cytolytic functions. Strikingly, in situ spatial analyses revealed that HLA-EHIGH tumors are activated to recruit NK and T cells via chemokine production, potentially sparing HLA-ELOW tumors that would otherwise be susceptible to lysis. Finally, blood-derived NK cells retained anti-tumor functions at the time of tumor recurrence. These data support combined NKG2A and PD-L1 blockade for BCG unresponsive disease.

Published
2022

10. The obesity paradox in metastatic castration resistant prostate cancer

Author

G.O. Cirulli, A. Martini, G. Gandaglia, N. Fossati, A. Necchi, D. Raggi, A. Stabile, V. Cucchiara, R. Leni, D. Robesti, F. Pellegrino, L. Nocera, S. Scuderi, P.I. Karakiewicz, M.D. Galsky, W.K. Oh, J.P. Sfakianos, A.B. Parikh, C. Tsao, F. Montorsi, and A. Briganti

Subjects
Urology
Published
2021

11. The inverse correlation between obesity and mortality in patients with metastatic castration resistant prostate cancer: Results from the control arms of ASCENT2, MAINSAL and VENICE trials

Author

Francesco Barletta, C.A. Bravi, Simone Scuderi, G. Fallara, G. Gandaglia, W.K. Oh, Giuseppe Rosiello, Luigi Nocera, M.D. Galsky, E.D. Gallagher, Alberto Martini, N. Fossati, Armando Stabile, Francesco Montorsi, A. Salonia, J.P. Sfakianos, A. Briganti, Giuseppe Cirulli, E. Mazzone, Daniele Robesti, and D. Cignoli

Subjects
Oncology, medicine.medical_specialty, business.industry, Urology, Castration resistant, lcsh:Diseases of the genitourinary system. Urology, lcsh:RC870-923, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, lcsh:RC254-282, Obesity, Prostate cancer, Internal medicine, medicine, In patient, business, Inverse correlation
Published
2020

12. Predicting toxicity-related Docetaxel discontinuation and survival in metastatic castration-resistant prostate cancer using open phase 3 trial data

Author

Andrea Necchi, M. Moschini, Francesco Barletta, C.A. Bravi, Giuseppe Rosiello, J.P. Sfakianos, N. Fossati, W.K. Oh, E. Mazzone, Daniele Robesti, G. Fallara, A.B. Parikh, Vito Cucchiara, Alberto Martini, C. Tsao, Simone Scuderi, Luigi Nocera, M.D. Galsky, Riccardo Leni, A. Briganti, Giuseppe Basile, Francesco Montorsi, G. Gandaglia, and Donato Cannoletta

Subjects
Oncology, medicine.medical_specialty, business.industry, Urology, Castration resistant, lcsh:Diseases of the genitourinary system. Urology, lcsh:RC870-923, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, lcsh:RC254-282, Discontinuation, Prostate cancer, Docetaxel, Internal medicine, Toxicity, medicine, business, medicine.drug
Published
2020

Catalog

Books, media, physical & digital resources
See catalog results